Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2024 Feb 20;14(1):4243.
doi: 10.1038/s41598-024-52748-3.

Analysis of related factors for RA flares after SARS-CoV-2 infection: a retrospective study from patient survey

Rong Li  1 , Jun-Kang Zhao  1 , Qian Li  1 , Li Zhao  1 , Ya-Zhen Su  1 , Jun-Yan Zhang  2 , Li-Yun Zhang  3
Affiliations
Multicenter Study

Analysis of related factors for RA flares after SARS-CoV-2 infection: a retrospective study from patient survey

Rong Li et al. Sci Rep. .

Abstract

SARS-CoV-2 and its variants are widely prevalent worldwide. With frequent secondary and breakthrough infections, immune dysfunction in RA patients, and long-term use of immune preparations, SARS-CoV-2 infection poses a significant challenge to patients and rheumatologists. Whether SARS-CoV-2 infection causes RA flares and what factors aggravate RA flares are poorly studied. A questionnaire survey was conducted on RA patients infected with SARS-CoV-2 after December 7, 2022, in China through a multicenter and inter-network platform regarding general personal condition, primary disease, comorbidity, SARS-CoV-2 vaccination, viral infection, and impact on the primary disease. A total of 306 RA patients were included in this study, and the patient data were analyzed, in which the general condition of RA patients, medication use before SARS-CoV-2 infection and post-infection typing and manifestations, and medication adjustment did not affect the Flare of RA patients after SARS-CoV-2 infection. The control of disease before SARS-CoV-2 infection (OR = 2.10), RA involving pulmonary lesions (OR = 2.28), and the recovery time of COVID-19 (OR = 2.50) were risk factors for RA flare. RA involving pulmonary lesions, control status of disease before infection, and recovery time of COVID-19 disease are risk factors for RA flare after SARS-CoV-2 infection.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Figure 1
Figure 1
Process flowchart of questionnaire collection information.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Khasnis AA, Schoen RT, Calabrese LH. Emerging viral infections in rheumatic diseases. Semin. Arthritis Rheum. 2011;41(2):236–246. doi: 10.1016/j.semarthrit.2011.01.008. - DOI - PubMed
    1. Yousefghahari B, Navari S, Sadeghi M, et al. Risk of COVID-19 infection in patients with rheumatic disease taking disease-modifying anti-rheumatic drugs. Clin. Rheumatol. 2021;40(10):4309–4315. doi: 10.1007/s10067-021-05779-4. - DOI - PMC - PubMed
    1. Louthrenoo W. Treatment considerations in patients with concomitant viral infection and autoimmune rheumatic diseases. Best Pr. Res. Clin. Rheumatol. 2015;29(2):319–342. doi: 10.1016/j.berh.2015.05.010. - DOI - PubMed
    1. Carabelli, A. M., Peacock, T. P., Thorne, L. G., et al. SARS-CoV-2 variant biology: immune escape, transmission and fitness. Nat. Rev. Microbiol. Published online January 18 (2023). 10.1038/s41579-022-00841-7 - PMC - PubMed
    1. Yıldırım, R., Üsküdar Cansu, D., Dinler, M., Korkmaz, C. Reactivation in major organ involvement following SARS-CoV-2 mRNA vaccination in Behçet's syndrome patient receiving immunosuppressive therapy. Rheumatology. 2022;61(SI2):SI197-SI199. 10.1093/rheumatology/keac246 - PMC - PubMed

Publication types

Substances